NeuWave Medical develops and commercializes innovative, energy-based, soft tissue ablation devices for various clinical markets.
NeuWave Medical, headquartered in Madison, WI, develops and commercializes innovative, energy-based, soft tissue ablation devices for interventional oncology, surgery and other clinical markets. The company is currently commercializing their market-leading Certus 140™ ablation system and continuing the pioneering development of novel interventional and surgical tools.
The Certus 140™ uses microwave energy at 2.45GHz, a subset of the radiofrequency spectrum, to ablate soft tissue. The system is designed to be used during both minimally invasive percutaneous procedures and open surgery. It is engineered to be the premier soft tissue ablation system available worldwide, maximizing power delivery to create large, predictable ablation zones.